![Cornerstone Advisors, Inc. closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io Cornerstone Advisors, Inc. closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io](https://images.fintel.io/us-VRTX-cornerstone-advisors1.png)
Cornerstone Advisors, Inc. closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io
![BlackRock Inc. ownership in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io BlackRock Inc. ownership in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io](https://images.fintel.io/us-VRTX-blackrock.png)
BlackRock Inc. ownership in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io
![Rampart Investment Management Company, LLC closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io Rampart Investment Management Company, LLC closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io](https://images.fintel.io/us-VRTX-rampart-investment-management-company-llc.png)
Rampart Investment Management Company, LLC closes position in VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io
![Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/10/16/51411522-16028509890305824_origin.png)
Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha
![Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/10/16/51411522-16028499693593345_origin.png)
Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20% ( NASDAQ:VRTX) | Seeking Alpha
VRTX - European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
Vertex Pharmaceuticals' (NASDAQ:VRTX) investors will be pleased with their impressive 139% return over the last five years | Nasdaq
![BlackRock Fund Advisors reports 8.86% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io BlackRock Fund Advisors reports 8.86% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated - 13F, 13D, 13G Filings - Fintel.io](https://images.fintel.io/us-VRTX-blackrock-fund-advisors.png)